Manel Cascalló
Corporate Officer/Principal at THERIVA BIOLOGICS, INC.
Manel Cascalló active positions
| Companies | Position | Start | End |
|---|---|---|---|
| THERIVA BIOLOGICS, INC. | Corporate Officer/Principal | 23/03/2022 | - |
Career history of Manel Cascalló
Former positions of Manel Cascalló
| Companies | Position | Start | End |
|---|---|---|---|
VCN Biosciences SL
 VCN Biosciences SL Miscellaneous Commercial ServicesCommercial Services Part of Theriva Biologics, Inc., VCN Biosciences SL is a clinical-stage immuno-oncology company based in Barcelona, Spain. The Spanish company focuses on developing the next generation of oncolytic adenoviruses that can obtain clinical activity after systemic administration and remodel the complex matrix in the tumor to allow enhanced spreading of therapeutic molecules and the immune system. VCN Biosciences' lead product, VCN-01, is a unique oncolytic adenovirus being studied in clinical trials for cancers for which there is no cure, including pancreatic carcinoma and retinoblastoma. The company was founded by Ramon Alemany. VCN Biosciences was acquired by Theriva Biologics, Inc. from Grifols SA on March 10, 2022 for $92.02 million. | Chief Executive Officer | - | - |
| Chairman | - | - |
Training of Manel Cascalló
| University of Barcelona | Doctorate Degree |
Statistics
International
| Spain | 3 |
| United States | 2 |
Operational
| Chief Executive Officer | 1 |
| Chairman | 1 |
| Corporate Officer/Principal | 1 |
Sectoral
| Commercial Services | 2 |
| Health Technology | 2 |
| Consumer Services | 2 |
Positions held
Active
Inactive
Listed companies
Private companies
Linked companies
| Listed companies | 1 |
|---|---|
| THERIVA BIOLOGICS, INC. | Health Technology |
| Private companies | 1 |
|---|---|
VCN Biosciences SL
VCN Biosciences SL Miscellaneous Commercial ServicesCommercial Services Part of Theriva Biologics, Inc., VCN Biosciences SL is a clinical-stage immuno-oncology company based in Barcelona, Spain. The Spanish company focuses on developing the next generation of oncolytic adenoviruses that can obtain clinical activity after systemic administration and remodel the complex matrix in the tumor to allow enhanced spreading of therapeutic molecules and the immune system. VCN Biosciences' lead product, VCN-01, is a unique oncolytic adenovirus being studied in clinical trials for cancers for which there is no cure, including pancreatic carcinoma and retinoblastoma. The company was founded by Ramon Alemany. VCN Biosciences was acquired by Theriva Biologics, Inc. from Grifols SA on March 10, 2022 for $92.02 million. | Commercial Services |
- Stock Market
- Insiders
- Manel Cascalló
- Experience
